Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …

(IL-6), based on the hypothesis that SARS-CoV-2 creates injury to the lung and other organs
in part through activation of cytokine and downstream proinflammatory networks. While …

Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

Summary Objectives Multiple RCTs of interleukin-6 (IL-6) inhibitors in COVID-19 have been
published, with conflicting conclusions. We performed a meta-analysis to assess the impact …

This study investigated the efficacy and safety of interleukin-6 (IL-6) receptor antagonists
with standard care treatment in patients with coronavirus disease 2019 (COVID-19). The …

Background: Interleukin-6 (IL-6) is known to be detrimental in coronavirus disease 2019
(COVID-19) because of its involvement in driving cytokine storm. This systematic review and …

Introduction Preliminary studies showed that coronavirus disease 2019 (COVID-19) disrupts
body immune system, including dysregulation of cytokine interleukin-6 (IL-6). IL-6 inhibitors …

Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

Importance The longer-term effects of therapies for the treatment of critically ill patients with
COVID-19 are unknown. Objective To determine the effect of multiple interventions for …

Background We systematically reviewed the literature to answer the following research
questions:(1) Does interleukin 6 (IL-6)(receptor) antagonist therapy reduce mortality in …